ILS Launches ILS Genomics Via the First Acquisition in Company History

Published: Jun 29, 2012

RESEARCH TRIANGLE PARK, N.C. – June 29, 2012 – Today, ILS announced the first acquisition in its company history with the purchase of key assets from the Morrisville, NC site of Beckman Coulter Genomics and the formation of ILS Genomics. ILS Genomics’ expertise in molecular genotyping, gene expression and biologics product safety testing are a perfect combination with ILS’ internationally recognized track record in toxicology, histopathology, genetic toxicology, and environmental & information sciences. On a global basis, leading customers receive a broad span of services in a highly customer-focused environment and as a result receive a combination unmatched in most companies.

“We are very pleased to add the top flight team from ILS Genomics,” said Dr. TK Rao, Chairman and Founder of ILS. “With this purchase, ILS continues its investment in people and innovative technology and is proud to enhance Research Triangle Park, NC as the leading bio/pharmaceutical hub in the United States.”

ILS Genomics has served 23 of the top 25 pharmaceutical companies in the world, delivering services ranging from research-stage to manufacturing, including clinical-grade work under current Good Laboratory Practices and current Good Manufacturing Practices in the US. The facility also holds quality certificates from European Medicines and Healthcare products Regulatory Agency (MHRA) and the Australian Therapeutic Goods Administration (TGA).

“With the addition of ILS Genomics we have expanded our scientific breadth and taken another significant step in realizing our strategic growth plans”, said Dr. Tom Goldsworthy, President and CEO of ILS. “Sam Tetlow is named General Manager of ILS Genomics and will lead the Company. We are very excited about the terrific combination of capabilities and services that this brings for our organization and customers.”

ILS Genomics delivers world-class services for genotyping, gene expression analysis, and biologics product safety testing. Gene expression profiling, the most commonly accepted method for clinical trial submissions of molecular data to regulatory agencies, and genotyping, are a particular strengths. ILS Genomics has a proven capability in all key platforms of gene expression profiling, including Affymetrix, Illumina, Agilent, Sequenom and ABI. Biologics product lot safety testing is an established area of expertise in the team for a large and growing customer base.

“ILS Genomics is very well positioned to benefit from well-known and enduring trends in the marketplace. Through focused, collaborative work with our customers we provide current and future services that are as trustworthy as they are dependable,” said Sam C. Tetlow, Chief Business Officer of ILS, who will also lead ILS Genomics as General Manager. “With the retention of a superb team, the acquisition of premium assets, and the revitalization of the quality infrastructure of ILS Genomics we are further realizing ILS’ vision of Advancing Science, Improving Lives.”

About ILS

Advancing Science, Improving Lives. ILS is a leading life sciences services company that provides research support to federal and commercial clients. Among ILS’ core capabilities are investigative toxicology, genetic toxicology, molecular biology, histopathology, and environmental and information science services. These services are provided to a host of clients, including leading life sciences companies and the National Institute of Environmental Health Sciences, and the U.S. Environmental Protection Agency. Based in Research Triangle Park, NC, ILS was founded by Chairman Dr. Thomas. K. Rao in 1985 and has 170 employees. For more information about ILS, visit


Sam C. Tetlow

Chief Business Officer, ILS

General Manager, ILS Genomics

(919) 281-1110 x710

Back to news